1

Alkermes

#2769

Rank

$4.77B

Marketcap

IE Ireland

Country

Alkermes
Leadership team

Mr. Richard F. Pops (Chairman & CEO)

Mr. Iain Michael Brown (Sr. VP & CFO)

Mr. Blair C. Jackson (Exec. VP & COO)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Dublin, Dublin, Ireland
Established
1987
Company Registration
SEC CIK number: 0001520262
Revenue
Above - 1B
Traded as
ALKS
Social Media
Overview
Location
Summary
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
History

Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland with an operational base in Waltham, Massachusetts. Its branches in Ireland, the U.S. and Continental Europe conduct corporate operations, including research and development (R&D), manufacturing, financing, and sales and marketing.

Mission
Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.
Vision
Alkermes’ vision is to develop, manufacture and commercialize new medications and drug-delivery technologies to address the unmet medical needs of patients.
Key Team

Mr. David Joseph Gaffin (Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec.)

Dr. Craig C. Hopkinson M.D. (Exec. VP of R&D and Chief Medical Officer)

Ms. Sandra Coombs (Sr. VP of Corp. Affairs & Investor Relations)

Dr. Floyd E. Bloom M.D. (Founder)

Mr. Thomas Harvey (Chief Information Officer & Sr. VP of IT)

Mr. Michael J. Landine (Sr. VP of Corp. Devel. & Chief Risk Officer)

Mr. Stephen Schiavo (Sr. VP of HR)

Recognition and Awards
Alkermes has won several awards over the years, including two separate Tibbetts Awards from the Small Business Administration for the company’s innovative work in the discovery, development and commercialization of pharmaceuticals. Alkermes also won Ireland’s Innovation Award in 2016 for the development of a new treatment for multiple sclerosis.
References
Alkermes
Leadership team

Mr. Richard F. Pops (Chairman & CEO)

Mr. Iain Michael Brown (Sr. VP & CFO)

Mr. Blair C. Jackson (Exec. VP & COO)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Dublin, Dublin, Ireland
Established
1987
Company Registration
SEC CIK number: 0001520262
Revenue
Above - 1B
Traded as
ALKS
Social Media